Gene sequencing technology company 10x Genomics (NASDAQ: TXG) hasn't been having it easy in the past few days on the stock market. A bearish analyst move dampened sentiment on the company, and ...

In the assessment of 12-month price targets, analysts unveil insights for 10x Genomics, presenting an average target of ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results , but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the ...

Link: https://www.zacks.com/commentary/2820228/3-medical-info-systems-stocks-to-gain-from-digitization-despite-industry-woes The Medical Info Systems industry ...

Combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection enables a deeper, more holistic understanding of tissue organization "The continued expansion of ...

Investors usually find it discouraging when an analyst cuts the price target on one of their stocks. In this instance, the cut to this company's shares was rather deep. It wasn't immediately apparent ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...